JP2018516937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516937A5 JP2018516937A5 JP2017562994A JP2017562994A JP2018516937A5 JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5 JP 2017562994 A JP2017562994 A JP 2017562994A JP 2017562994 A JP2017562994 A JP 2017562994A JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- composition
- item
- eudragit
- constipation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171462P | 2015-06-05 | 2015-06-05 | |
| US62/171,462 | 2015-06-05 | ||
| US201662339462P | 2016-05-20 | 2016-05-20 | |
| US62/339,462 | 2016-05-20 | ||
| PCT/US2016/035886 WO2016197042A1 (en) | 2015-06-05 | 2016-06-03 | Modified or targeted release formulations of linaclotide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166911A Division JP2021001223A (ja) | 2015-06-05 | 2020-10-01 | リナクロチドの改変または標的放出製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516937A JP2018516937A (ja) | 2018-06-28 |
| JP2018516937A5 true JP2018516937A5 (enExample) | 2019-07-04 |
Family
ID=56133109
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562994A Pending JP2018516937A (ja) | 2015-06-05 | 2016-06-03 | リナクロチドの改変または標的放出製剤 |
| JP2020166911A Withdrawn JP2021001223A (ja) | 2015-06-05 | 2020-10-01 | リナクロチドの改変または標的放出製剤 |
| JP2022164508A Withdrawn JP2022179727A (ja) | 2015-06-05 | 2022-10-13 | リナクロチドの改変または標的放出製剤 |
| JP2024140831A Pending JP2024161048A (ja) | 2015-06-05 | 2024-08-22 | リナクロチドの改変または標的放出製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166911A Withdrawn JP2021001223A (ja) | 2015-06-05 | 2020-10-01 | リナクロチドの改変または標的放出製剤 |
| JP2022164508A Withdrawn JP2022179727A (ja) | 2015-06-05 | 2022-10-13 | リナクロチドの改変または標的放出製剤 |
| JP2024140831A Pending JP2024161048A (ja) | 2015-06-05 | 2024-08-22 | リナクロチドの改変または標的放出製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190350863A1 (enExample) |
| EP (1) | EP3302440B1 (enExample) |
| JP (4) | JP2018516937A (enExample) |
| ES (1) | ES2868873T3 (enExample) |
| WO (1) | WO2016197042A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA47112A (fr) * | 2016-12-21 | 2019-10-30 | Ironwood Pharmaceuticals Inc | Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide |
| CN114206324A (zh) * | 2019-06-10 | 2022-03-18 | 硬木药品公司 | 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛 |
| WO2022002369A1 (en) * | 2020-06-30 | 2022-01-06 | Ocvirk Soeren | Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591713A (en) * | 2008-08-15 | 2013-07-26 | Ironwood Pharmaceuticals Inc | Solid stable formulations of linaclotide for oral administration |
| US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
| JP2013501071A (ja) * | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ， インコーポレイテッド | リナクロチドを含む処方物 |
| EP3626253B8 (en) * | 2010-08-11 | 2022-04-20 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| BR112014007753B1 (pt) * | 2011-09-30 | 2021-07-06 | Astellas Pharma Inc. | composição farmacêutica granular, formulação e método para produção |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
-
2016
- 2016-06-03 WO PCT/US2016/035886 patent/WO2016197042A1/en not_active Ceased
- 2016-06-03 JP JP2017562994A patent/JP2018516937A/ja active Pending
- 2016-06-03 ES ES16729739T patent/ES2868873T3/es active Active
- 2016-06-03 EP EP16729739.9A patent/EP3302440B1/en active Active
-
2019
- 2019-07-30 US US16/525,784 patent/US20190350863A1/en not_active Abandoned
-
2020
- 2020-10-01 JP JP2020166911A patent/JP2021001223A/ja not_active Withdrawn
-
2022
- 2022-03-11 US US17/692,280 patent/US20220202725A1/en not_active Abandoned
- 2022-10-13 JP JP2022164508A patent/JP2022179727A/ja not_active Withdrawn
-
2024
- 2024-08-22 JP JP2024140831A patent/JP2024161048A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101799625B1 (ko) | 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물 | |
| KR101799624B1 (ko) | 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물 | |
| El-Zahaby et al. | Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate | |
| CA2984434C (en) | Monolithic tablets based on carboxyl polymeric complexes for controlled drug release | |
| JP2017504590A5 (enExample) | ||
| JP2013522373A (ja) | 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形 | |
| HRP20231699T1 (hr) | Formulacije inhibitora amorfne kinaze i postupci njihove primjene | |
| KR20130086128A (ko) | 복용 용이성 고형 제제 | |
| JP6768070B2 (ja) | 粘膜付着性医薬組成物及びその製造方法 | |
| CN103269691A (zh) | 用于控制释放美沙拉嗪的口服药物片剂和其获得方法 | |
| CN105025888B (zh) | 肠溶片 | |
| WO2017022248A1 (ja) | 腸溶性カプセル | |
| JP2018516937A5 (enExample) | ||
| Iswandana et al. | Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form | |
| Ramli et al. | Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment | |
| CN110475557B (zh) | 固体分散体 | |
| Segale et al. | Calcium alginate multi-unit oral dosage form for delayed release of celecoxib | |
| Newton et al. | Effect of HPMC-E15 LV premium polymer on release profile and compression characteristics of chitosan/pectin colon targeted mesalamine matrix tablets and in vitro study on effect of pH impact on the drug release profile | |
| CN105078997A (zh) | 一种利伐沙班药用组合物及其制备方法 | |
| Kim et al. | Preparation of hydroxypropylmethyl cellulose-based porous matrix for gastroretentive delivery of gabapentin using the freeze-drying method | |
| CN118234489A (zh) | 吡啶酮衍生物的口服制剂及其在肠纤维化的预防和/或治疗中的用途 | |
| Tiwari et al. | Enhancement of site specific delivery of diloxanide furoate as an antiamoebic drug | |
| Patil et al. | Development and Evaluation of Mesalamine Tablet Formulation for Colon Delivery | |
| CA3060026A1 (en) | Polymer based formulation for release of drugs and bioactives at specific git sites | |
| Elghamry et al. | Formulation and evaluation of colon targeted pulsincap delivery of Carvedilol for treatment of hypertension |